| Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) N Mavaddat, D Barrowdale, IL Andrulis, SM Domchek, D Eccles, ... Cancer Epidemiology and Prevention Biomarkers 21 (1), 134-147, 2012 | 447 | 2012 |
| Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk FJ Couch, X Wang, L McGuffog, A Lee, C Olswold, KB Kuchenbaecker, ... PLoS Genet 9 (3), e1003212, 2013 | 264 | 2013 |
| Identification of six new susceptibility loci for invasive epithelial ovarian cancer KB Kuchenbaecker, SJ Ramus, J Tyrer, A Lee, HC Shen, J Beesley, ... Nature genetics 47 (2), 164-171, 2015 | 217 | 2015 |
| Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells A Vazquez‐Martin, R Colomer, J Brunet, R Lupu, JA Menendez Cell proliferation 41 (1), 59-85, 2008 | 190 | 2008 |
| Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells JA Menendez, A Vazquez-Martin, R Colomer, J Brunet, ... BMC cancer 7 (1), 80, 2007 | 179 | 2007 |
| Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer RL Milne, KB Kuchenbaecker, K Michailidou, J Beesley, S Kar, ... Nature genetics 49 (12), 1767-1778, 2017 | 154 | 2017 |
| POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and … F Bellido, M Pineda, G Aiza, R Valdés-Mas, M Navarro, DA Puente, ... Genetics in Medicine 18 (4), 325-332, 2016 | 152 | 2016 |
| Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer CM Phelan, KB Kuchenbaecker, JP Tyrer, SP Kar, K Lawrenson, ... Nature genetics 49 (5), 680, 2017 | 149 | 2017 |
| Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: A population‐based study S de Sanjosé, M Leone, V Berez, A Izquierdo, R Font, JM Brunet, T Louat, ... International journal of cancer 106 (4), 588-593, 2003 | 132 | 2003 |
| New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis L Valle, E Hernández-Illán, F Bellido, G Aiza, A Castillejo, MI Castillejo, ... Human molecular genetics 23 (13), 3506-3512, 2014 | 125 | 2014 |
| Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene LS Schmidt, ML Nickerson, D Angeloni, GM Glenn, MCM Walther, ... The Journal of urology 172 (4 Part 1), 1256-1261, 2004 | 121 | 2004 |
| Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers KB Kuchenbaecker, L McGuffog, D Barrowdale, A Lee, P Soucy, J Dennis, ... JNCI: Journal of the National Cancer Institute 109 (7), 2017 | 117 | 2017 |
| Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75 T Puig, A Vázquez-Martín, J Relat, J Pétriz, JA Menéndez, R Porta, ... Breast cancer research and treatment 109 (3), 471-479, 2008 | 105 | 2008 |
| Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. L De Andres, J Brunet, A Lopez-Pousa, J Burgués, M Vega, JM Tabernero, ... Journal of clinical oncology 13 (6), 1493-1500, 1995 | 104 | 1995 |
| Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes L Feliubadaló, A Lopez-Doriga, E Castellsagué, J Del Valle, M Menéndez, ... European Journal of Human Genetics 21 (8), 864-870, 2013 | 102 | 2013 |
| An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa™)-induced changes in the expression and nucleo-cytoplasmic … L Ferrer-Soler, A Vazquez-Martin, J Brunet, JA Menendez, R De Llorens, ... International journal of molecular medicine 20 (1), 3-10, 2007 | 102 | 2007 |
| Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the … C Oliveras-Ferraros, A Vazquez-Martin, E López-Bonet, B Martín-Castillo, ... International journal of oncology 33 (6), 1165-1176, 2008 | 95 | 2008 |
| Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer CA Maxwell, J Benítez, L Gómez-Baldó, A Osorio, N Bonifaci, ... PLoS Biol 9 (11), e1001199, 2011 | 93 | 2011 |
| BRCA1 and acetyl‐CoA carboxylase: the metabolic syndrome of breast cancer J Brunet, A Vazquez‐Martin, R Colomer, B Graña‐Suarez, ... Molecular Carcinogenesis: Published in cooperation with the University of …, 2008 | 91 | 2008 |
| Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation R Salazar, C Sola, P Maroto, JM Tabernero, J Brunet, G Verger, V Valenti, ... Bone marrow transplantation 23 (1), 27-33, 1999 | 89 | 1999 |
